Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled glycopyrronium for sialorrhea in Parkinson disease
NL-OMON45524Phase 2Active, not recruiting
- Sponsor
- Medisch Spectrum Twente
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glycopyrronium in hypersalivation, sponsored by Medisch Spectrum Twente. Primary endpoint: Safety and tolerability of glycopyrronium inhalations. Started May 2017; status: active, not recruiting.
02
Drugs
glycopyrronium
03
Conditions
hypersalivation
Beyond the preview
Go deeper on NL-OMON45524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45524.